Ordering
Available Variants20 mg
CHA.76079-20mg
Price
€211.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
20 mg | CHA.76079-20mg | €211.20 |
phyproof® Reference Substance
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C15H20O3 |
|---|---|
| CAS Number | 20554-84-1 |
| Molecular Weight | 248.32 |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
| MDL number | MFCD00134592 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H317 |
| pcodes | P280 - P302 + P352 |
| Hazard Classifications | Skin Sens. 1 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Parthenolide, with the chemical formula C15H20O3 and CAS number 20554-84-1, is a sesquiterpene lactone naturally occurring in the feverfew plant. It has been extensively studied for its potential therapeutic applications, primarily due to its anti-inflammatory and anticancer properties. The compound has been shown to inhibit the nuclear factor kappa B pathway, leading to the suppression of various pro-inflammatory genes. Additionally, parthenolide has been found to induce apoptosis in several cancer cell lines, suggesting its potential as a chemotherapeutic agent. Its mechanism of action involves the inhibition of cell proliferation and the induction of cell cycle arrest, making it a promising candidate for the treatment of various types of cancer. Further research is needed to fully explore the therapeutic potential of parthenolide and to overcome the challenges associated with its clinical development.
